

## **A Fluorogenic, Small Molecule Reporter for Mammalian Phospholipase C Isozymes**

Weigang Huang<sup>1</sup>, Stephanie N. Hicks<sup>2</sup>, John Sondek<sup>2</sup>, Qisheng Zhang<sup>1\*</sup>


<sup>1</sup>*Division of Medicinal Chemistry and Natural Products, <sup>2</sup>Department of Pharmacology, The  
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599*

This document contains supporting figures (3 pages), experimental procedures and data (5  
pages), and NMR spectra of key compounds (17 pages)

**Page S2-4: Supplementary Figures**

**Page S5-9: Experimental Protocols and Data**

**Page S10-S26: NMR Spectra of Key Compounds**



**Figure S1. HPLC and LC-MS analyses confirm PLC- $\delta$ 1 cleaves WH-15 to generate free 6-aminoquinoline.** WH-15 (58  $\mu$ M, final concentration) was used in the PLC assay buffer as described in the Experimental with the presence of BSA, PLC- $\delta$ 1(E341A), or PLC- $\delta$ 1. The reaction was stopped by adding MeOH and the mixture was analyzed by HPLC. The column was eluted in a gradient that starts with 10% MeOH in H<sub>2</sub>O and ends with 100% MeOH in 10 min. The HPLC chromatograms for (A) BSA; (B) PLC- $\delta$ 1(E341A); (C) PLC- $\delta$ 1; and (D) co-injection of PLC- $\delta$ 1 sample (20  $\mu$ L) with 6-aminoquinoline (10  $\mu$ L of 1.0 mM in H<sub>2</sub>O) are shown. LC-MS (ESI-Pos) (E) analysis of the PLC- $\delta$ 1 sample after incubation with **WH-15** demonstrates the formation of a compound with the same molecular ion as 6-aminoquinoline.





Figure S2. Kinetic studies of WH-15 with PLC- $\delta$ 1 (A) and PLC- $\beta$ 2 (B).



**Figure S3. PLA2 and PLD did not generate fluorescence increase from WH-15.** (A) **WH-15** was incubated with PLA2 under conditions that were described in the Experimental and fluorescence was recorded. The relative fluorescence intensity is defined as the ratio of fluorescence reading to the initial reading in reaction mixture without PLA2 at  $t = 0$  min. (B) The same batch of PLA2 catalyzed the hydrolysis of dioleoylphosphatidylcholine (DOPC) to oleic acid and lysophosphatidylcholine under the same reaction conditions. Lysophosphatidylcholine was detected by  $^{31}\text{P}$ -NMR and mass spectrometry (MS). The specific activity of PLA2 was measured as 5.9 nmol/min/unit. (C) **WH-15** was incubated with PLD under conditions that were described in the Experimental and fluorescence was recorded. The relative fluorescence intensity is defined as the ratio of fluorescence reading to the initial reading in the reaction mixture without PLD at  $t = 0$  min. (B) The same batch of PLD catalyzed the hydrolysis of DOPC to dioleoylphosphatidic acid (DOPA) and choline under the same reaction conditions. DOPA was detected by  $^{31}\text{P}$ -NMR and MS. The specific activity of PLD was measured as 14.4 nmol/min/unit.

## Experimental

**General.** Chemicals were purchased from Aldrich and Acros Chemical Corporation and used without further purification. Solvents were purchased from suppliers as anhydrous grade. NMR spectra were recorded at room temperature on Gemini-300 MHz, Inova-400 MHz or Inova-500 MHz spectrometer. Chemical shifts are reported in ppm with TMS as the internal standard for  $^1\text{H}$  NMR and 85%  $\text{H}_3\text{PO}_4$  as the external standard for  $^{31}\text{P}$  NMR spectra. High-resolution mass spectra were obtained on a Bruker Daltonics (Billerica, Massachusetts) BioToF (ESI-TOF; Electrospray Time of Flight Mass Spectrometer) mass spectrometer or LTQ Orbitrap (Thermo Fisher Scientific, Bremen, Germany). HPLC analyses were performed on a Thermo Betasil C18 reverse phased column (150 x 4.6 mm, 5  $\mu\text{m}$ ) with the SHIMADZU LC-6AD system. Preparative HPLC was performed on a Thermo Betasil C18 reverse phase column (150 x 10 mm, 5  $\mu\text{m}$ ). Phospholipase  $\text{A}_2$  from honey bee venom and Phospholipase D from *Streptomyces chromofuscus* were purchased from Sigma.

### 4-Hydroxy-3-(octyloxy)benzaldehyde (3)

To the solution of 4-(benzyloxy)-3-hydroxybenzaldehyde (190 mg, 0.83 mmol) in anhydrous DMF (2.0 mL) was added 60% NaH (40 mg, 1.00 mmol) at 0  $^\circ\text{C}$  followed by the addition of 1-iodooctane (300 mg, 1.25 mmol). The reaction mixture was stirred at room temperature (r.t.) overnight and  $\text{NH}_4\text{Cl}$  solution was then added. The mixture was extracted with ethyl acetate 3 times and the combined organic layers were dried and concentrated under vacuum. The resulting residue was purified through flash column chromatography (Hexane: Ethyl Acetate = 10:1) to yield 4-(benzyloxy)-3-(octyloxy)benzaldehyde (235 mg, 83%) as light yellow oil, which was subsequently subjected to hydrogenolysis in ethyl acetate in the presence of 10% Pd/C. After filtration and concentration, the crude residue was purified by column chromatography (Hexane: Ethyl Acetate = 5:1) to give **3** (125 mg, 72%) as light yellow oil.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)  $\delta$  9.80 (s, 1H), 7.36–7.42 (m, 2H), 7.03 (d,  $J$  = 8.6 Hz, 1H), 6.44 (s, 1H), 4.09 (t,  $J$  = 6.9 Hz, 2H), 1.82 (hexatet,  $J$  = 6.7 Hz, 2H), 1.20–1.50 (m, 10H), 0.87 (t,  $J$  = 6.8 Hz, 3H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)  $\delta$  191.09, 151.96, 146.70, 129.90, 127.42, 114.44, 109.68, 69.30, 31.86, 29.37, 29.28, 29.09, 26.03, 22.73, 14.17; ESI-HRMS for  $[\text{M} + \text{H}]^+$

C<sub>15</sub>H<sub>23</sub>O<sub>3</sub>: calcd 251.1647, found 5251.1638.

#### **Benzyl 4-formyl-2-(octyloxy)phenyl diisopropylphosphoramidite (4)**

A solution of **3** (66.0 mg, 0.26 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> was added to the mixture of 1*H*-tetrazole (9.0 mg, 0.13 mmol) and 1-(benzyloxy)-*N,N,N',N'*-tetraisopropylphosphinediamine (1.0 M, in CH<sub>2</sub>Cl<sub>2</sub>) (0.53 mL, 0.53 mmol) at r.t. under argon. After stirring at r.t. for 3 h, the reaction mixture was concentrated and purified by column chromatography (Hexane: Acetone: TEA= 100: 5: 3) to give phosphoramidite **4** (127 mg, 100%) as colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 9.85 (s, 1H), 7.40 (d, *J* = 2.1 Hz, 1H), 7.24–7.37 (m, 6H), 7.20 (dd, *J* = 8.1 Hz, 1.8 Hz, 1H), 4.88 (dd, *J* = 12.4, 8.5 Hz, 1H), 4.82 (dd, *J* = 12.4, 8.5 Hz, 1H), 4.01 (t, *J* = 6.5 Hz, 2H), 3.74–3.88 (m, 2H), 1.72–1.85 (m, 2H), 1.41–1.52 (m, 2H), 1.20–1.38 (m, 20H), 0.88 (t, *J* = 7.3 Hz, 3 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 191.33, 151.57 (d, *J*<sub>CP</sub> = 2.3 Hz), 150.26 (d, *J*<sub>CP</sub> = 4.4 Hz), 139.48 (d, *J*<sub>CP</sub> = 7.4 Hz), 131.58, 128.39, 127.54, 127.09, 125.64, 120.10 (d, *J*<sub>CP</sub> = 12.5 Hz), 111.17, 68.86, 66.09 (d, *J*<sub>CP</sub> = 17.1 Hz), 43.85 (d, *J*<sub>CP</sub> = 13.1 Hz), 31.92, 29.50, 29.37, 26.22, 24.71, 24.62, 24.50, 22.76, 14.20; <sup>31</sup>P NMR (CDCl<sub>3</sub>, 162 MHz) δ 149.01 (s, 1P); ESI-HRMS for [M + Na]<sup>+</sup> C<sub>28</sub>H<sub>42</sub>NO<sub>4</sub>PNa: calcd 510.2749, found 510.2770.

#### **Compound 6**

A solution of phosphoramidite **4** (127 mg, 0.26 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (2.0 mL) was added to compound **5** (65 mg, 78 μmol) and 1*H*-tetrazole (29 mg, 0.39 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL) at r.t. in one portion under argon. The mixture was stirred at r.t. for 12 h, and a solution of *t*-BuOOH (5.0~6.0 M, 0.24 mL) in decane was added at -40 °C. The resulting reaction mixture was warmed to room temperature gradually, concentrated and purified by column chromatography (Hexane: Acetone= 2:1) to provide the product **6** (39 mg, 40%) as colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 9.90 (s, 1H), 7.53 (dd, *J* = 8.5, 8.2 Hz, 1H), 7.20–7.45 (m, 27H), 5.26 (conformation 1) and 5.24 (conformation 2) (2H), 4.85–5.15 (m, 9H), 4.57–4.80 (m, 4H), 4.51 (d, *J* = 6.6 Hz, 1H), 4.32–4.45 (m, 4H), 4.18 (dd, *J* = 16.0, 8.0 Hz, 1H), 3.94–4.05 (m, 2H), 3.55 (dd, *J* = 9.5, 7.4 Hz, 1H), 3.37 (conformation 1) and 3.32 (conformation 2) (s, 3H), 3.33 (conformation 2) and 3.27 (conformation 1) (s, 3H), 3.19

(s, 3H), 1.76 (hexatet,  $J = 6.9$  Hz, 2H), 1.20–1.44 (m, 10H), 0.87 (t,  $J = 6.9$  Hz, 3H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)  $\delta$  191.07, 151.07, 150.99, 144.49, 144.46, 144.38, 136.06, 136.03, 135.96, 135.93, 135.87, 135.77, 135.35, 135.33, 135.22, 134.45, 134.42, 134.41, 128.93, 128.88, 128.85, 128.74, 128.65, 128.59, 128.57, 128.55, 128.50, 128.16, 128.05, 128.00, 127.92, 124.82, 124.80, 124.66, 121.84, 121.79, 111.86, 98.89, 97.74, 96.75, 77.71, 77.40, 77.36, 77.01, 75.75, 74.41, 70.82, 70.74, 70.03, 69.94, 69.84, 69.79, 69.77, 69.72, 69.57, 69.50, 69.27, 56.83, 55.99, 55.93, 55.90, 31.92, 29.41, 29.39, 29.34, 29.06, 25.94, 25.91, 22.75, 14.22;  $^{31}\text{P}$  NMR ( $\text{CDCl}_3$ , 162 MHz)  $\delta$  conformation 1:  $-0.07$  (2P),  $-6.05$  (1P); conformation 2:  $-0.10$  (2P),  $-6.25$  (1P); ESI (Pos)-HRMS for  $[\text{M} + \text{Na}]^+ \text{C}_{62}\text{H}_{77}\text{O}_{20}\text{P}_3\text{Na}$ : calcd 1257.4119, found 1257.4169.

### Compound 7

Aldehyde **6** (30 mg, 24  $\mu\text{mol}$ ) in anhydrous THF (2.0 mL) was treated with  $\text{NaBH}_4$  (5.0 mg, 0.132 mmol) at r.t. under argon for 4 h. The reaction mixture was concentrated and purified by column chromatography (hexane: acetone = 2:1) to give the product **7** (28 mg, 95%) as colorless oil.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  7.25–7.38 (m, 26 H), 6.95 (s, 1H), 6.83 (d,  $J = 8.2$  Hz, 1H), 5.23–5.27 (m, 2H), 4.85–5.17 (m, 9H), 4.58–4.76 (m, 6H), 4.50 (dd,  $J = 6.9, 6.3$  Hz, 1H), 4.08–4.44 (m, 5H), 3.81–3.98 (m, 2H), 3.50 (dd,  $J = 11.3, 10.2$  Hz, 1H), 3.36 (conformation 1) and 3.32 (conformation 2) (s, 3H), 3.33 (conformation 2) and 3.27 (conformation 1) (s, 3H), 3.19 (s, 3H), 1.76 (tt,  $J = 7.4, 7.0$  Hz, 2H), 1.20–1.44 (m, 10H), 0.87 (t,  $J = 6.5$  Hz, 3H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz)  $\delta$  150.45, 150.40, 139.32, 139.27, 138.98, 138.91, 136.26, 136.16, 136.15, 136.07, 135.79, 135.71, 128.67, 128.60, 128.52, 128.44, 128.35, 128.20, 128.15, 128.04, 127.84, 121.75, 121.72, 121.47, 121.45, 118.97, 118.91, 112.46, 98.84, 97.72, 96.60, 96.36, 78.87, 77.36, 75.69, 75.60, 74.50, 74.41, 74.17, 70.42, 70.12, 69.86, 69.80, 69.70, 69.64, 69.60, 69.54, 69.35, 69.30, 69.09, 69.05, 65.10, 56.87, 56.85, 55.94, 55.88, 31.96, 29.49, 29.46, 29.38, 29.31, 26.04, 26.00, 22.78, 14.24;  $^{31}\text{P}$  NMR ( $\text{CDCl}_3$ , 162 MHz):  $\delta$  conformation 1: 0.07 (2P),  $-5.34$  (1P); conformation 2: 0.04 (2P),  $-5.44$  (1P); ESI-HRMS for  $[\text{M} + \text{Na}]^+ \text{C}_{62}\text{H}_{79}\text{O}_{20}\text{P}_3\text{Na}$ : calcd 1259.4275, found 1259.4267. The  $^{31}\text{P}$  NMR signals of the two conformers collapsed when the temperature of measurement increases to 50  $^\circ\text{C}$ .

## Compound WH-15

The mixture of compound **7** (20 mg, 16  $\mu\text{mol}$ ), 4-Dimethylaminopyridine (DMAP) (12 mg, 100  $\mu\text{M}$ ) and N-(quinolin-6-yl)-1*H*-imidazole-1-carboxamide **8** (12 mg, 50  $\mu\text{mol}$ ) was stirred in anhydrous acetonitrile (3.0 mL) under argon at 60 °C. The reaction was monitored by TLC (Hexane: acetone=1:1) on silica gel. After 4 h, the reaction mixture was concentrated and subjected to a flash column purification (Hexane:acetone = 1.5:1) to remove most of the starting material **6** and DMAP. The purified compound **9** was dried and re-dissolved in anhydrous  $\text{CH}_2\text{Cl}_2$  (2.0 mL). Bromotrimethylsilane (2.0 mL) was then added at -10 °C under argon. The reaction mixture was slowly warmed to r.t. and stirred for another 2 h. The solvents and volatile compounds were removed by evaporation, and the residue was dried under vacuum for 1 h. Methanol (4.0 mL) was subsequently added and stirred at r.t. for 2 h. After removal of the solvent, the residue was dried under vacuum for 2 h. Then the crude product was re-dissolved in 30% MeOH and purified by HPLC on a Thermo Betasil C18 reverse Phase column (150 x 10 mm, 5  $\mu\text{m}$ ). The desired fractions were combined to give the product (5 mg, 36%) as white solid. The compound was treated with 1.0 M TEAB buffer to form the triethyl amine salt, which was stable at -20 °C for 2 months.  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ , 400 MHz)  $\delta$  8.6 (d,  $J = 3.6$  Hz, 1H), 8.16 (d,  $J = 8.4$  Hz, 1H), 8.06 (s, 1H), 7.84 (d,  $J = 9.0$  Hz, 1H), 7.66 (d,  $J = 9.0$  Hz, 1H), 7.48 (d,  $J = 8.2$  Hz, 1H), 7.39 (dd,  $J = 8.4, 4.3$  Hz, 1H), 6.96 (s, 1H), 6.84 (d,  $J = 7.7$  Hz, 1H), 5.06 (s, 2H), 4.30 (dd,  $J = 17.9, 8.8$  Hz, 1H), 4.22 (br. s, 1H), 4.07 (dd,  $J = 7.7, 8.4$  Hz, 1H), 3.85–3.96 (m, 4H), 3.51 (d,  $J = 9.3$  Hz, 1H), 1.71 (tt,  $J = 7.8, 6.9$  Hz, 2H), 1.30–1.41 (m, 2H), 1.10–1.30 (m, 8H), 0.77 (t,  $J = 6.9$  Hz, 3H);  $^{13}\text{C}$  NMR ( $\text{CD}_3\text{OD}$ , 126 MHz)  $\delta$  155.89, 151.52 (d,  $J_{\text{CP}} = 6.0$  Hz), 149.63 (d,  $J_{\text{CP}} = 9.9$  Hz), 145.55, 144.06 (d,  $J_{\text{CP}} = 6.0$  Hz), 139.17, 137.86, 133.54, 130.70, 129.78, 124.59, 123.05, 122.42, 121.74, 115.46, 115.41, 115.29, 80.22, 78.36, 72.94 (d,  $J_{\text{CP}} = 9.9$  Hz), 72.39, 70.57, 67.82, 60.28, 33.18, 30.70, 30.62, 30.53, 27.23, 23.87, 14.61;  $^{31}\text{P}$  NMR ( $\text{CD}_3\text{OD}$ , 162 MHz)  $\delta$  3.88 (1P), 3.11 (1P), -3.39 (1P); ESI (Pos)-HRMS for  $[\text{M} + \text{H}]^+$   $\text{C}_{31}\text{H}_{44}\text{N}_2\text{O}_{18}\text{P}_3$ : calcd 825.1799, found 825.1793.

### *Phospholipase A2 (PLA2) Assay*


The reporter **WH-15** (50  $\mu\text{M}$ ) was dissolved in the assay buffer (10  $\mu\text{L}$ ) that contains



150 mM of NaCl and 5 mM of CaCl<sub>2</sub> at 37 °C. The assay was initiated by the addition of 2 μL of PLA2 (10 unit/mL, Sigma). The fluorescence was measured as described above. For the control reaction to demonstrate PLA2 is functional, dioleoylphosphatidylcholine (DOPC) was used instead of **WH-15** under otherwise identical conditions. The enzymatic product lysophosphatidylcholine was detected by <sup>31</sup>P-NMR and mass spectrometry (MS). The specific activity of PLA2 was measured as 5.9 nmol/min/unit.

#### *Phospholipase D (PLD) Assay*



The reporter **WH-15** (50 μM) was dissolved in the assay buffer (10 μL) that contains 12.4 mM of Tris (pH 8.4), 3.1 mM of SDS, and 50 mM of CaCl<sub>2</sub>. The assay was initiated by the addition of 2 μL of PLD (10 unit/mL, Sigma). The fluorescence was measured as described above. For the control reaction to demonstrate PLD is functional, DOPC was used instead of **WH-15** under otherwise identical conditions. The enzymatic product dioleoylphosphatidic acid (DOPA) was detected by mass spectrometry (MS) and <sup>31</sup>P-NMR. The specific activity of PLD was measured as 14.4 nmol/min/unit.



20090409\_4-25-1\_CDCl3\_C13  
 334

SAMPLE 9 2009  
 date Apr 9 2009  
 solvent CDCl3  
 file exp  
 ACQUISITION 75.458  
 sfrq C13  
 tn dmm  
 at 1.706  
 nd 64000  
 sw 18751.7  
 fb 9500  
 bs 8  
 pw 8.0  
 dl 1.000  
 tof 0  
 nt 1024  
 ct 80  
 alock p  
 gain not used  
 flags  
 i1 n  
 in n  
 dp y  
 DISPLAY  
 SP -1835.4  
 WD 18751.7  
 VS 100  
 SC 0  
 WC 240  
 hzmm 0.91  
 ts 500.00  
 rfl 7657.1  
 rfp 5821.8  
 th 9  
 ins 100.000  
 nm  
 no ph



DEC. & VT 300.062  
 dn HL  
 dnp 1.0  
 dot 0  
 yyy w  
 PROCESSING 1.00  
 dmf 7200  
 lb  
 wifile  
 proc 65536  
 ft





090619\_4-25-1

exp1 PHOSPHORUS



SAMPLE	Jun 19 2009	satmode	n
date	Jun 19 2009	satmode	n
solvent	cdcl3	wet	n
file	/home/UNC/vnm~	SPECIAL	26.0
rsys	/data/UNC/NB_I~	gain	50.0
v	0.001/NB_IV_0001	sp in	20.0
PHOSPHORUS	071.f1d	nst	9.100
ACQUISITION	33783.8	pw90	0.008
sw	0.970	atfa	10.000
at	65536	11	n
np	22400	in	nw
fb	64	dp	Y
bs	1.000	hs	mn
d1	64	1b	0.50
nt	64	fn	not used
ct	64	sp	33782.8
tn	161.872	wp	811.5
sfrq	20316.6	rf1	0
tof	51	ffp	-54.8
tpwr	4.550	fp	0
pw	DECOUPLER	tp	0
dn	H1	WC	240
dof	0	SC	0
dm	mny	VS	45
decwawe	W	th	18
dpwr	40	ai	cdc
dmf	9662	ph	










Parameter	Value
1 Title	5-61_4-27-1
2 Solvent	cdcl3
3 Pulse Sequence	s2pul
4 Acquisition Date	2009-11-30T07:25:50
5 Temperature	26.0
6 Number of Scans	512
7 Spectrometer Frequency	161.86
8 Spectral Width	41666.7
9 Lowest Frequency	-8694.7
10 Nucleus	31P
11 Acquired Size	32768
12 Spectral Size	65536









Parameter	Value
1 Title	5-95_4-29-1
2 Solvent	cdcl3
3 Pulse Sequence	s2pul
4 Acquisition Date	2009-12-02T13:04:41
5 Temperature	26.0
6 Number of Scans	20000
7 Spectrometer Frequency	100.54
8 Spectral Width	25510.2
9 Lowest Frequency	-1679.7
10 Nucleus	<sup>13</sup> C
11 Acquired Size	32768
12 Spectral Size	65536





Parameter	Value
1 Title	5-71_4-29-1
2 Solvent	cdcl3
3 Pulse Sequence	s2pul
4 Acquisition Date	2009-11-30T07:06:52
5 Temperature	26.0
6 Number of Scans	512
7 Spectrometer Frequency	161.86
8 Spectral Width	41666.7
9 Lowest Frequency	-8694.7
10 Nucleus	<sup>31</sup> P
11 Acquired Size	32768
12 Spectral Size	65536



4-29-1 CDC13 P31 at -17  
exp9 s2pu1

date	Aug 3 2010	dfrq	DEC. & VT	499.749
solvent	CDC13	dn		H1
file	/export/home/~	dpwr		35
qzhang	/vnmr/sy/da-	dof		49.2
ta/WGHUANG	/20100809	dm		yyy
3_4-29-1_P31	m1153	dmm		w
	17.74	dmt		87.42
ACQUISITION	0	dseq		
sfrq	202.311	dres		1.0
tn	p31	homo		n
at	1.600	temp		-17.0
np	194236			
sw	60698.0	dfrq2	DEC2	0
fb	33000	dn2		1
bs	16	dpwr2		0
tpwr	63	dof2		n
pw	15.0	dm2		0
d1	0	dmm2		C
tof	15148.5	dseq2		9900
nt	256	dres2		1.0
ct	256	homo2		n
alock	n			
gain	60	dfrq3	DEC3	0
fl	n	dn3		1
in	n	dpwr3		0
dp	y	dof3		n
hs	ny	dm3		n
		dmm3		C
sp	DISPLAY	dmt3		9900
wp	-1260.5	dseq3		1.0
vs	1474.5	dres3		n
sc	40	homo3		n
wc	250			
hzzm	5.90	lb	PROCESSING	5.00
is	28.57	wffile		
rfl	20233.8	proc		ft
rflp	0	fn		not used
th	0	math		f
ins	5	werr		
nm	cdc	wexp		
	ph	wbs		
		wnt		








4-29-1 CDCl3 P31 at 50  
exp9 s2pu1

SAMPLE 3 2010 DEC. & VT 499.749  
 solvent CDCl3 H1  
 title /export/home/~ qpwr 33  
 qszhang/vnmrsys/da~ dof 49.2  
 te/WGHUANG/2010080~ dm yyvz 25  
 3\_4-29-1\_P31\_50.f1~ dmm wss 1.0  
 d dmf 8742.0

ACQUISITION  
 sfrq 202.311 dseq 1.0  
 tn p31 homo 1  
 at 1.600 temp 50.0  
 np 194236 DECE2  
 sw 60698.0 dfrq2 0  
 fb 33000 dn2 1  
 bs 16 dpwr2 0  
 tpwr 63 dof2 n  
 pw 15.0 dm2 n  
 dl 0 dmm2 c  
 tof 15148.5 dmft2 9900  
 nt 256 dseq2 n  
 ct 256 dres2 1.0  
 n homo2 n  
 gain 60 DECE3  
 f1 dn3 0  
 in n dpwr3 1  
 dp y dof3 0  
 hs ny dms n  
 dm3 c  
 dmm3 n  
 DISPLAY -1729.2 dmft3 9900  
 wp 2312.7 dres3 1.0  
 vs 34 homos 0  
 sc 0 hmos3 n  
 wc 250 lb PROCESSING 5.00  
 hzmm 9.25 wfttle  
 ls 28.97 proc  
 rftl 20233.8 fn  
 rfp 0 math not used  
 th 6  
 ins 1.000  
 nm cdc ph  
 werr wexp  
 wbs  
 wnt







Parameter	Value
1 Title	5-77_5-15_HPLC-8
2 Solvent	cd3od
3 Pulse Sequence	s2pul
4 Acquisition Date	2009-11-05T08:23:32
5 Temperature	26.0
6 Number of Scans	512
7 Spectrometer Frequency	399.83
8 Spectral Width	6410.3
9 Lowest Frequency	-837.3
10 Nucleus	1H
11 Acquired Size	16384
12 Spectral Size	32768

20091218\_5-15\_CD300\_C13  
 exp3 s2pu1

SAMPLE Dec 17 2009  
 solvent cd3od  
 file ACQUISITION  
 srfreq 125.674  
 tn C13  
 at 1.300  
 np 65372  
 sw 25133.5  
 fb 14000  
 bs 256  
 tpwr 60  
 pw 6.0  
 dl 0  
 tof 461.3  
 nt 204800  
 ct 69632  
 alock n  
 gain 60  
 flags n  
 i1 n  
 in n  
 dp n  
 hs y  
 DISPLAY 0.3  
 sp wd 25132.8  
 vs 2875  
 sc 0  
 wc 250  
 hzmm 100.53  
 fs 1646.71  
 rfi 6176.8  
 rfp 6176.3  
 th 5  
 ins 100.000  
 nm cdc ph



DEC. & VT 499.751  
 dn H1  
 dpr 37  
 dof -549.9  
 dm 155.887  
 dmm 151.547  
 dmf 151.954  
 dseq 149.267  
 dres 149.177  
 homo 149.588  
 temp 145.547  
 dfrq2 0  
 dn2 1  
 dpwr2 1  
 dof2 0  
 dm2 n  
 dmm2 C  
 dmf2 10000  
 dseq2 1  
 dres2 n  
 homo2 n  
 dfrq3 0  
 dn3 1  
 dpwr3 1  
 dof3 0  
 dm3 n  
 dmm3 C  
 dmf3 10000  
 dseq3 1  
 dres3 n  
 homo3 n  
 PROCESSING 1.00  
 lb wtfile  
 proc ft  
 fn not used  
 math f  
 werr  
 wexp  
 wbs  
 wnt

180  
160  
140  
120  
100  
80  
60  
40  
20  
ppm



Parameter	Value
1 Title	5-77_5-15_HPLC-8
2 Solvent	cd3od
3 Pulse Sequence	spul
4 Acquisition Date	2009-11-05T09:49:24
5 Temperature	26.0
6 Number of Scans	1024
7 Spectrometer Frequency	161.86
8 Spectral Width	41666.7
9 Lowest Frequency	-8694.4
10 Nucleus	31P
11 Acquired Size	32768
12 Spectral Size	65536

<sup>31</sup>P NMR (162 MHz, cd<sub>3</sub>od) δ 2.53, 1.76, -4.74.






5-15\_Cosy

Sample Name: S-15\_Cosy  
Data Collected on: GMB400-Vmrs400  
Archive directory: /home/UNC/vmrsys/data/wghuang  
Sample directory: 05\_986  
FidFile: 05\_986\_gCOSY\_001

Pulse Sequence: gCOSY  
Solvent: cd3od  
Data collected on: Dec 20 2009

Temp: 26.0 C / 299.1 K  
Sample #13, Operator: wghuang

Relax. delay: 1.000 sec  
Acq. time: 0.150 sec  
Width: 4864.2 Hz  
2D Width: 4864.2 Hz  
Single scan  
512 increments  
OBSERVE H1, 399.8173940 MHz  
DATA PROCESSING  
Sd. sine bell: 0.075 sec  
F1 DATA PROCESSING  
Sd. sine bell: 0.080 sec  
F2 size: 4096 x 4096  
Total time: 11 min



WH-15

